


Daring to Go Beyond

CELLTRION EARNINGS RELEASE

FOURTH-QUARTER and FULL YEAR 2025

2026.02.05



Disclaimer

The financial information contained in this document is consolidated earnings results based on K-IFRS.

This document is provided for the convenience of investors only before the external audit is completed. The audit outcomes may cause some changes in this document.

This document contains 'forward-looking statements' related to the business performance, market condition, future events and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.

01

2025 Financial Highlights & 2026 Outlook

2025 at a Glance

Biosimilars

11 products
in the portfolio

Record-High Revenue

Exceeded
KRW 4tn
(YoY +17.0%)

Record-High Operating Profit

Exceeded
KRW 1tn
(YoY +137.5%)

Revenue contribution from Young Portfolio

54%
(38% in 2024)

U.S. Facility Acquisition

Eliminating tariff risks &
diversifying production sites

Clinical Trial Kicked Off for New Drugs

CT-P70

CT-P71

CT-P72

CT-P73

Shareholder Return

Treasury Shares:
KRW 840bn Acquired
KRW 900bn Cancelled

Cash Dividend:
KRW 750/share

4Q25 Financial Highlights



Powered by Continued Growth in High-Margin Young Products,
Record-High Quarterly Revenue and OP, Highest OPM Since the Merger

[Unit: KRW billion]

	4Q25	3Q25	QoQ	4Q24	YoY
Sales	1,330.2	1,029.0	+29.3%	1,063.6	+25.1%
Biologics	1,252.3	961.3	+30.3%	873.2	+43.4%
Non-Biologics	77.9	67.7	+15.1%	190.4	-59.1%
Operating Profit	475.2	301.4	+57.7%	196.4	+142.0%
OP Margin	35.7%	29.3%	+6.4%p	18.5%	+17.2%p

Sales Increased+25.1% YoY

- Quarterly sales grew +25% YoY, driven by strong growth in biologics; high-margin young portfolio surged +82% YoY
- All five new launches planned for commercialization in 2025 were successfully launched within the year, with rapid early uptake contributing to sales growth

OP Increased+142.0% YoY


- As merger-related effects have fully normalized, a stronger young-product mix lowered COGS while sales-driven SG&A leverage lifted operating margin to 36%
- With continued growth in prescriptions for the young portfolio, further margin expansion is expected going forward.

Biologics Global Market Sales




- Growth momentum bolstered by strong sales of high-margin young products
- 4Q25 Young Portfolio sales reached KRW 734.7 bn (YoY +82%), with contribution nearing 60%, a record high
- FY25 global biologics sales totaled KRW 3,863.8 bn(YoY +24%), with Young Portfolio accounting for 54% of sales—the contribution is expected to expand further to ~70% in 2026

Quarterly Comparison



Annual Forecast




* Advanced: Remsima, Truxima, Herzuma / Young: RemsimaSC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, Omlyclo, Stoboclo & Osenvelt, etc.
* 2023: Pre-merger Celltrion Healthcare's sales

Biologics Sales (by Product)




- Within Advanced Portfolio, Remsima maintained stable sales, while Truxima and Herzuma continued to grow
- Key young products(Remsima SC/Zymfentra, Yuflyma, Vegzelma) continues to deliver strong growth; combined global sales YoY+44%
- Given the rapid prescription uptake of 5 new products launched in 2025, high-margin young product sales growth is expected to accelerate

Advanced Products ▲ KRW 47.5 bn



High-margin Young Products ▲ KRW 331.6 bn


[Unit: KRW billion]



* 5 new products: Steqeyma, Stoboclo & Osenvelt, Avtozma, Omlyclo, Eydenzelt
* Advanced Products: Launched before 2020 / Young Products: Launched between 2020–2024 / 5 new products: Launched in 2025 and thereafter

2026 Guidance

High-Margin Products Expansion and Stable Cost Structure **Boost Profitability and Earnings Growth**
Biosimilar & Novel Drug Pipeline Expansion **Reinforces Growth Foundation**



1. UC: Ulcerative Colitis

Balance Sheet

▪ Net debt increased following the acquisition of the Branchburg manufacturing facility in the U.S.; however, the debt ratio remains stable in the 20% range, significantly below the average of large conglomerates

Statement of Financial Position Summary


[Unit: KRW billion]

Category	End of 2024	End of 2025
Total Assets	21,055	22,361
Current Assets	5,584	6,232
- Cashable Assets ¹	1,143	1,237
- Trade Receivables	1,215	1,790
- Inventory Assets	2,766	2,804
Non-current Assets	15,471	16,130
- Intangible Assets	13,702	13,778
Total Liabilities	3,475	5,009
Current Liabilities	3,187	4,480
Non-current Liabilities	288	529
* Borrowings (Long- and Short-term)	2,162	3,690
Shareholder's Equity	17,580	17,353
Issued Capital	221	239
Share Premium	14,803	14,190
Retained Earnings	3,744	4,407
Accumulated other comprehensive income	563	310
Other components of equity	(1,891)	(1,938)

1. Cashable Assets : cash and cash equivalent, and short-term financial instrument

Net Debt and Debt-Equity Ratio

[Unit: KRW billion]



1. Net debt: borrowings (long & short term) – cashable assets

2. Debt to Equity Ratio: total liabilities /shareholder's equity


3. Average debt ratio of large conglomerates (manufacturing sector) based on the Bank of Korea's "Corporate Management Analysis." The figure labeled as 2025 represents a debt ratio as of Q3 2025.




02

Global Commercial Update

- Sustained strong market share across Europe and the U.S., reinforcing the global leadership in the infliximab market



* Based on infliximab IV market (Excluding SC)
 * Source: IQVIA




* Based on infliximab IV market (Excluding SC)
 * Source: IQVIA, Symphony Health

Truxima (Rituximab) & Herzuma (Trastuzumab)




- Truxima maintained stable market share in the 30% range in both the U.S. and Europe
- Herzuma continued to hold no.1 biosimilar position in Europe with a sustained upward trend while further strengthening its dominant position in Japan. Market share is expected to expand further following the planned launch of Herzuma SC



* Market share based on prescription volume

* Source: IQVIA, Symphony Health




* Market share based on prescription volume

* Source: IQVIA


Remsima SC & Zymfentra (Infliximab SC)



- Remsima SC’s EU5 market share reached 30% for the first time
- Zymfentra in the U.S. secured over 90% insurance coverage, driving rapid prescription growth as weekly prescriptions hit record highs



1. Based on EU5 infliximab market
* Data based on SC dose-adjusted prescription volume * Source: IQVIA




* Source: IQVIA SMART WSP (Weekly Sales Perspectives)


Launch of the World's First and Only Liquid Infliximab



IFX¹ market growth driven by Celltrion



World's only IFX brand with SC, lyophilized, and liquid formulations, driving further M/S expansion





* Source: IQVIA
1. IFX: Infliximab

Yuflyma (Adalimumab) & Vegzelma (Bevacizumab)




- Yuflyma: maintained strong sales momentum with a leading market position in Europe (3Q25 M/S 24%) and rising U.S. prescriptions → A strong 2026 growth driven by expanded Low-WAC product sales and optimized rebate efficiency
- Vegzelma: held No.1 in Europe(3Q25 M/S 26%) and expanded U.S. presence(4Q25 M/S 9%) via channel diversification, driving global revenue



Global Sales Trend of Five New Products

- Surpassed KRW 300bn in annual sales within its debut year despite late-2025 launch
- 2026 revenue set for rapid growth with full-year sales contribution



Global status of Five New Products	
 ustekinumab	▪ Launched in Europe (24.11) and the U.S. (25.03) → Delivered early tangible results, including tender wins in major markets and rapid formulary inclusion by major PBMs
 denosumab &  denosumab	▪ Launched in Europe (25.12) and the U.S. (25.07) → Exclusive preferred drug listing with one of the top 3 U.S. PBMs
 omalizumab	▪ Launched in Europe (25.09) → Launched as the first mover with no competing products → Market leadership accelerated by the addition of a PFS formulation
 tocilizumab	▪ Launched in Europe (26.01) and the U.S. (25.10) → Secured contracts with French private hospital groups and Spanish public tenders immediately upon European launch → U.S. PBM listings progressing smoothly
 afilibercept	▪ Launched in Europe (25.12) → Secured major UK tenders immediately upon launch, establishing an early supply base



03

Development & Production Strategy


Biosimilar R&D Update

▪ Building on successful 2025 pipeline launches, next-generation pipeline development progressing smoothly

R&D Progress

Indication	Pipeline	Global Market Size (2024)	R&D Status	
			US	EU
Autoimmune Diseases	CT-P53 (biosimilar of OCREVUS®)	\$8.2bn	In Phase 3 Clinical Trial	
	CT-P55 (biosimilar of COSENTYX®)	\$9.9bn	In Phase 3 Clinical Trial	
	CT-P52 (biosimilar of TALTZ®)	\$7.0bn	In Phase 1 Clinical Trial	
	CT-P45 (Undisclosed molecule)	-	IND submission planned	
	CT-P68 (Undisclosed molecule)	-	IND submission planned	
Oncology therapy	CT-P6 SC (biosimilar of HERCEPTIN SC®)	\$1.3bn ²	Regulatory filing planned	
NSCLC ¹	CT-P51 (biosimilar of KEYTRUDA®)	\$32.7bn	In Phase 3 Clinical Trial	
Multiple Myeloma	CT-P44 (biosimilar of DARZALEX®)	\$11.7bn	In Phase 3 Clinical Trial	

Portfolio Status




* Source: IQVIA, J&J(DARZALEX)

1. NSCLC: Non-Small Cell Lung Cancer

2. Based on the Trastuzumab market in Europe (2024)

Biosimilar Portfolio Expansion Roadmap




* Source: IQVIA, Globaldata

Novel Drug Development Timeline



▪ Key clinical readouts expected in 2026-2027 with global clinical trials advancing across regions



Open Innovation Partnerships for Novel Drug Development

- Partnering with domestic and global biotechs for in-licensing, platform development, and co-development

	2022	2023	2024	2025
Antibody	 CT-P70, CT-P71, CT-P73   CT-P72 	 NBD 04 		 NBD 18   R&D Collaboration   CT-P77, NBD 19 
Microbiome	 R&D Collaboration 	 R&D Collaboration   R&D Collaboration 	 R&D Collaboration 	 R&D Collaboration 
Cell & Gene Therapy		 R&D Collaboration   Strategic Investment 		
AI			 R&D Collaboration 	 R&D Collaboration   R&D Collaboration   R&D Collaboration 
Small Molecule				 R&D Collaboration   R&D Collaboration 
Peptide				 R&D Collaboration 

SC Platform: Hyaluronidase Biosimilar Development

Proprietary SC formulation technology

- **World's first infliximab SC**
Successful commercialization of "Remsima SC/Zymfentra"
- Protected by **proprietary patents** through 2040
- 2025 Global sales exceeding KRW 800 billion (YoY +40%)
- **Continued creation of new demand** within the infliximab market

Hyaluronidase Platform Secured & Product Application Completed

Hyaluronidase biosimilar CT-P67 development completed

Applied in Herzuma SC & BLA submission on track

To apply to further SC products, with planned expansion into CMO

- **World's first & only** hyaluronidase biosimilar

- **World's first & only** trastuzumab SC biosimilar
- **Regulatory submissions** underway

- **Accelerating development of follow-on SC pipelines** leveraging CT-P67
- Expansion planned into **SC formulation-conversion CMO business**

Building an end-to-end in-house SC full value chain

from development through commercialization, beyond simple technology out-licensing

Operational Plan for Branchburg Site in the U.S.

Operations	[2026 2Q~] Full-scale operations to commence - CMO production to begin immediately with revenue contribution; operational stability secured through Eli Lilly contract - Validation of in-house products to be initiated; additional products to be added in line with mid to long-term capacity expansion plans
Capacity Expansion	[Phased Capacity Expansion] 2026 66,000L + ~2028 33,000L + ~2030 33,000L Total 132,000L [Strategic Benefits] - Improved operational leverage and cost structure through capacity expansion - Enhanced supply-chain resilience through in-house manufacturing in the U.S. - Capital-efficient expansion leveraging existing facilities, enabling faster execution and lower capex versus greenfield development.



04

Appendix

Earnings Summary Consolidated



Quarterly

	4Q24	1Q25	2Q25	3Q25	4Q25
Sales	1,064	842	962	1,029	1,330
Cost of Sales	520	399	417	403	477
Gross Profit	544	443	544	626	854
GP Margin	51.1%	52.6%	56.6%	60.8%	64.2%
SG&A	347	294	302	325	379
- R&D Expenses	61	56	46	55	53
Operating Profit	196	149	243	301	475
OP Margin	18.5%	17.7%	25.2%	29.3%	35.7%
Profit before Income Tax	274	196	52	378	528
Net Profit	236	108	63	332	528
NP Margin	22.2%	12.9%	6.6%	32.3%	39.7%

Annual

[Unit: KRW billion]

	2024	2025	YoY
Sales	3,557	4,163	17.0%
Cost of Sales	1,876	1,696	-9.6%
Gross Profit	1,682	2,467	46.7%
GP Margin	47.3%	59.3%	12.0%p
SG&A	1,190	1,299	9.2%
- R&D Expenses	200	211	5.5%
Operating Profit	492	1,169	137.5%
OP Margin	13.8%	28.1%	14.3%p
Profit before Income Tax	576	1,154	100.3%
Net Profit	419	1,032	146.2%
NP Margin	11.8%	24.8%	13.0%p

* Figures are rounded to the nearest KRW 1 billion; minor discrepancies may occur due to rounding

Sales Mix by Product

Quarterly

	4Q24	1Q25	2Q25	3Q25	4Q25
Sales	1,064	842	962	1,029	1,330
Biologics	873	768	883	961	1,252
Advanced Products	470	420	415	440	518
Remsima IV	289	238	261	265	285
Truxima	132	129	103	126	169
Herzuma	49	54	51	49	64
Young Products	403	347	468	521	735
Remsima SC	170	135	161	185	236
Yuflyma	108	118	137	144	104
Vegzelma	77	59	80	75	155
Zymfentra	28	13	23	28	58
Steqeyma	18	21	35	35	42
Omlyclo	-	0	22	28	49
Eydenzelt	3	0	2	2	6
Stoboclo/Osenvelt	-	1	7	20	71
Avtozma	-	-	1	4	14
Non-Biologics	190	74	79	68	78
CT Pharm/Chemical	79	68	72	63	70
CMO	106	-	-	-	-
Others	6	6	7	5	8

Annual

[Unit: KRW billion]

	2024	2025	YoY
Sales	3,557	4,163	17.0%
Biologics	3,109	3,864	24.3%
Advanced Products	1,915	1,793	-6.4%
Remsima IV	1,269	1,050	-17.3%
Truxima	450	526	17.1%
Herzuma	197	217	10.1%
Young Products	1,193	2,071	73.6%
Remsima SC	564	717	27.1%
Yuflyma	349	503	44.0%
Vegzelma	221	369	66.8%
Zymfentra	37	122	233.9%
Steqeyma	20	134	586.7%
Omlyclo	-	99	New Product
Eydenzelt	3	9	252.0%
Stoboclo/Osenvelt	-	99	New Product
Avtozma	0	19	New Product
Non-Biologics	449	299	-33.4%
CT Pharm/Chemical	320	274	-14.5%
CMO	106	-	-100%
Others	23	25	8.2%

* Figures are rounded to the nearest KRW 1billion; minor discrepancies may occur due to rounding

Advanced Therapeutics within Everyone's Reach

Thank you